Clinical Trials Sponsored by Suzhou Kanova Biopharmaceutical Co., LTD

Total 885 results

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Completed

ADME Study of [14C]-Jaktinib in Healthy Male Subjects

Healthy Adult Male Volunteers

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Completed

Jaktinib Versus Hydroxycarbamide in Subjects With Intermediate-2 or High-risk Myelofibrosis

Myelofibrosis

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Completed

Study of Jaktinib In Patients With Myelofibrosis Who Were Relapsed or Refractory of Ruxolitinib Treatment.

Myelofibrosis

China
Advaccine (Suzhou) Biopharmaceuticals Co., Ltd.

Active, not recruiting

Safety and Efficacy of BARS13 in the Elderly

Respiratory Syncytial Virus Infections

Australia
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Active, not recruiting

The Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Terminated

A Study of Donafenib Monotherapy in Advanced Oesophageal Cancer

Oesophageal Cancer

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Terminated

Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AML

Acute Myeloid Leukemia (AML)

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Completed

Safety and Efficacy of Topical Recombinant Human Thrombin(rhThrombin) for Surgical Hemostasis

Surgical Hemostasis

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Enrolling by invitation

Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric Cancer

Perioperative Treatment in Subjects With Locally Advanced Resectable Gastric Cancer or Gastroesophageal Junction Cancer

China
Advaccine (Suzhou) Biopharmaceuticals Co., Ltd.

Completed

A First in Human Study to Evaluate the Safety and Immune Response to a Vaccine for the Treatment of a Respiratory Virus, When Administered Into the Arm in Healthy Adult Participants

Respiratory Syncytial Virus Infections

Australia
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Recruiting

A Phase 1/2 Study of Donafenib in Combination With KN046 in Advanced Gastrointestinal Tumors

Advanced Gastrointestinal Tumors

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Tigermed Consulting Co., Ltd

Completed

Safety and Efficacy of Donafenib in Patients With Advanced Hepatocellular Carcinoma

HCC

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Tigermed Consulting Co., Ltd

Completed

Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma

HCC

China
SUNHO（China）BioPharmaceutical CO., Ltd.

Not yet recruiting

A Clinical Trial to Evaluate Effect of IBD0333 in Patients With Advanced Malignant Tumors

MTD
SUNHO（China）BioPharmaceutical CO., Ltd.

Recruiting

To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Metastatic Colorectal Cancer

HER2 Gene Mutation

China
SUNHO（China）BioPharmaceutical CO., Ltd.

Recruiting

A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors

Advanced Malignant Tumors

China
SUNHO（China）BioPharmaceutical CO., Ltd.

Recruiting

Clinical Study of IAH0968 in Patients With HER2-positive Advanced Solid Tumors

Advanced Solid Tumor

China
SUNHO（China）BioPharmaceutical CO., Ltd.

Not yet recruiting

A Study of IAP0971 in Combination With Bacillus Calmette Guerin in High Risk Non-muscular Invasive Bladder Cancer

Bladder Cancer
SUNHO（China）BioPharmaceutical CO., Ltd.

Recruiting

A Clinical Trial to Evaluate Effect of IBB0979 in Patients With Advanced Malignant Tumors

Advanced Malignant Tumors

China
SUNHO（China）BioPharmaceutical CO., Ltd.

Recruiting

A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors

Advanced Malignant Tumors

China
SUNHO（China）BioPharmaceutical CO., Ltd.

Recruiting

IAH0968 in Combination With GC for the Treatment of HER2-Positive Unresectable Advanced/Metastatic Malignant Tumors

HER2 Gene Mutation

China
SUNHO（China）BioPharmaceutical CO., Ltd.

Recruiting

A Clinical Trial to Evaluate the Effect of IAE0972 in Patients With Advanced Malignant Solid Tumors.

Advanced Malignant Solid Tumor

China
SUNHO（China）BioPharmaceutical CO., Ltd.

Recruiting

Clinical Trial of IBC0966 in Patients With Advanced Malignant Tumors

Advanced Malignant Tumors

China
Suzhou Connect Biopharmaceuticals, Ltd.

Active, not recruiting

A Study to Evaluate the Safety and Efficacy of CBP-201 in Chinese Adult Subjects With Moderate to Severe AD

Atopic Dermatitis

China
Suzhou Connect Biopharmaceuticals, Ltd.

Completed

A Study to Evaluate the Pharmacokinetics Similarity of CBP-201 in Healthy Adult Chinese Subjects

Healthy Adult Subjects

China
Suzhou Connect Biopharmaceuticals, Ltd.

Terminated

A Study to Evaluate CBP-201, Rademikibart, in Adult Patients With Chronic Rhinosinusitis With Nasal Polyps

Chronic Rhinosinusitis With Nasal Polyps

United States, China, Poland, Spain, Ukraine
Suzhou Connect Biopharmaceuticals, Ltd.

Completed

A Study On Human Mass Balance And Biotransformation

Healthy Adult Subjects

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
CStone Pharmaceuticals

Recruiting

A Study of CS1001 in Combination With Donafenib in Subjects With Advanced Solid Tumors

Advanced Solid Tumor

China
Inovio Pharmaceuticals
Advaccine (Suzhou) Biopharmaceuticals Co., Ltd.

Terminated

Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) | Coronavirus Infection | COVID-19 Disease

United States, Mexico, Colombia
Suzhou Connect Biopharmaceuticals, Ltd.

Completed

A Study Assessing the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC)

Moderate to Severe Ulcerative Colitis

United States, China, Pakistan, Ukraine
Suzhou Connect Biopharmaceuticals, Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of CBP-201 in Moderate to Severe Atopic Dermatitis in China

Moderate-to-severe Atopic Dermatitis

China
Suzhou Connect Biopharmaceuticals, Ltd.

Completed

Efficacy and Safety of CBP-201 in Patients With Moderate to Severe Persistent Asthma With Type 2 Inflammation

Moderate to Severe Persistent Asthma

United States, China, Hungary, Korea, Republic of, Poland
Suzhou Connect Biopharmaceuticals, Ltd.

Completed

A Study to Assess the Efficacy and Safety of CBP-201 in Adult Subjects With Moderate to Severe Atopic Dermatitis

Moderate-to-severe Atopic Dermatitis

United States, Australia, China, New Zealand
Suzhou Connect Biopharmaceuticals, Ltd.

Withdrawn

CBP-201 in Adolescent and Adult Patients With Moderate-to-severe Atopic Dermatitis

Atopic Dermatitis

United States
AskGene Pharma, Inc.
Suzhou Aosaikang Biopharmaceutical Co., Ltd.

Not yet recruiting

A Study of ASKG712 in Patients With Diabetic Macular Edema

Diabetic Macular Edema

China
AskGene Pharma, Inc.
Suzhou Aosaikang Biopharmaceutical Co., Ltd.

Recruiting

A Study of ASKG712 in Patients With Neovascular Age-Related Macular Degeneration

Neovascular Age-related Macular Degeneration

China
Fujian Cancer Hospital
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Subjects With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma (REVO)

Esophageal Neoplasms | Esophageal Squamous Cell Carcinoma

China
Zai Biopharmaceutical (Suzhou) Co., Ltd.

Completed

A Study of ZL-1211 in Patients With Advanced Solid Tumor

Advanced Solid Tumor

United States, China
Suzhou Connect Biopharmaceuticals, Ltd.
Tigermed Consulting Co., Ltd; Nucleus Network Ltd

Completed

Phase 1 Study Accessing the Safety and Tolerability of CBP-307

Autoimmune Diseases

Australia
Suzhou Kintor Pharmaceutical Inc,
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Recruiting

A Phase Ib/II Study of GT90001 Combined With KN046 in Solid Tumors

Solid Tumor

Taiwan
Hasten Biopharmaceutical Co., Ltd.

Recruiting

Efficacy and Safety of Mexartan Potassium Tablets (AZL-M) and Calcium Channel Blockers (CCB) in the Treatment of Adults With Essential Hypertension in Chinese Population: a National Multicenter, Prospective, Observational Study

Essential Hypertension

China
Binhui Biopharmaceutical Co., Ltd.

Recruiting

oHSV2-PD-L1/CD3-BsAb Administered Via Intramural Injection

Solid Tumor

United States
Xuanzhu Biopharmaceutical Co., Ltd.

Not yet recruiting

A Study of KM501 in Patients With Solid Tumors

Advanced Solid Tumors

China
Xuanzhu Biopharmaceutical Co., Ltd.

Not yet recruiting

A Study of Anaprazole Sodium Enteric-coated Tablets in the Treatment of Reflux Esophagitis

Gastrointestinal Diseases | Gastroesophageal Reflux | Esophageal Motility Disorders | Deglutition Disorders | Esophageal Diseases | Esophagitis | Reflux Esophagitis

China
Xuanzhu Biopharmaceutical Co., Ltd.

Not yet recruiting

Drug-drug Interaction Study of XZP-3621 Tablet

Healthy Subjects

China
Binhui Biopharmaceutical Co., Ltd.

Recruiting

OH2 Oncolytic Viral Therapy in Advanced Bladder Cancer

Advanced Bladder Carcinoma

China
Xuanzhu Biopharmaceutical Co., Ltd.

Recruiting

A Phase I Study of XZP-3621 in Chinese Patients With ALK or ROS1 Rearrangement Non-small Cell Lung Cancer

ROS1 Rearrangement Non-small Cell Lung Cancer | ALK Rearrangement Non-small Cell Lung Cancer

China
Beijing Tsinghua Chang Gung Hospital
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Recruiting

Donafenib Combined With Hepatic Artery Chemoembolization for Perioperative Treatment of Liver Transplantation

Hepatocellular Carcinoma

China
Binhui Biopharmaceutical Co., Ltd.

Not yet recruiting

OH2 Administered by Intratumoral Injection

Solid Tumor
Xuanzhu Biopharmaceutical Co., Ltd.

Not yet recruiting

A Study of XZB-0004 in Patients With Solid Tumors

NSCLC | Advanced Solid Tumor

China

Clinical Trials Sponsored by Suzhou Kanova Biopharmaceutical Co., LTD

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Estonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations